Cargando…

D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants

BACKGROUND: D-dimer levels measured during and after vitamin K antagonist withdrawal may be used in clinical practice to assess the individual risk of recurrent venous thromboembolism. Currently, direct oral anticoagulants (DOACs) are frequently used in venous thromboembolism treatment; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legnani, Cristina, Martinelli, Ida, Palareti, Gualtiero, Ciavarella, Alessandro, Poli, Daniela, Ageno, Walter, Testa, Sophie, Mastroiacovo, Daniela, Ciammaichella, Maurizio, Bucherini, Eugenio, Mumoli, Nicola, Cosmi, Benilde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634858/ https://www.ncbi.nlm.nih.gov/pubmed/31310608 http://dx.doi.org/10.1371/journal.pone.0219751

Ejemplares similares

Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study
por: Palareti, Gualtiero, et al.
Publicado: (2019)

COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Cost‐minimization analysis of venous thromboembolism diagnosis: Comparison of standalone imaging with a strategy incorporating D‐dimer for exclusion of venous thromboembolism
por: Verma, Karan, et al.
Publicado: (2017)

An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
por: Cini, Michela, et al.
Publicado: (2019)

Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study
por: Poli, Daniela, et al.
Publicado: (2019)

Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study
por: Poli, Daniela, et al.
Publicado: (2018)

The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
por: Antonucci, Emilia, et al.
Publicado: (2015)

Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study
por: Menichelli, Danilo, et al.
Publicado: (2021)

Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
por: Ageno, Walter, et al.
Publicado: (2023)

Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis
por: Pompilio, Giuseppe, et al.
Publicado: (2020)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
por: Moustafa, Farès, et al.
Publicado: (2017)

Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago
por: Palareti, Gualtiero, et al.
Publicado: (2017)

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
por: Capecchi, Marco, et al.
Publicado: (2022)

Managing anticoagulation in the COVID-19 era between lockdown and reopening phases
por: Poli, Daniela, et al.
Publicado: (2020)

Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
por: Poli, Daniela, et al.
Publicado: (2022)

Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register
por: Antonucci, Emilia, et al.
Publicado: (2020)

Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
por: Palareti, Gualtiero
Publicado: (2012)

Extended anticoagulation after venous thromboembolism: should it be done?
por: Fernandes, Caio J., et al.
Publicado: (2019)

Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register
por: Poli, Daniela, et al.
Publicado: (2022)

Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Thromboembolism and anticoagulation after Fontan surgery
por: Viswanathan, Sangeetha
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2021)

Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
por: Douketis, James, et al.
Publicado: (2011)

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2019)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_pcsnqv2ss1af9t4k1ks485pb00